From FGFR3 Hyperactivation to Disease-Modifying Therapy in Pediatric Achondroplasia: Molecular Mechanisms, Clinical Evidence, and Emerging Treatments.
Vosoritide has shown potential to improve growth velocity in children with achondroplasia, but uncertainties remain about long-term outcomes and safety.
Where it sits
this study against the rest of the vosoritide corpusSummary and findings
This narrative review synthesizes evidence on achondroplasia, focusing on its genetic basis, molecular mechanisms, and emerging therapies such as vosoritide. Vosoritide has shown potential in pharmacologically modulating FGFR3-related signaling to improve growth velocity. The review emphasizes the need for further research on long-term outcomes and safety.
Abstract
<h4>Background/objectives</h4>Achondroplasia is the most common genetic skeletal dysplasia associated with disproportionate short stature and is primarily caused by gain-of-function variants in the fibroblast growth factor receptor 3 (FGFR3) gene. Constitutive FGFR3 activation disrupts growth plate homeostasis and endochondral ossification through complex alterations in chondrocyte proliferation, differentiation, hypertrophy, extracellular matrix organization, and intracellular signaling. The increasing understanding of these mechanisms has enabled the transition from exclusively supportive management toward disease-modifying and precision-based therapeutic strategies. This narrative review aimed to critically synthesize current evidence on the genetic basis, molecular pathogenesis, growth plate abnormalities, and current and emerging targeted therapies in achondroplasia.<h4>Methods</h4>A narrative literature review was conducted using PubMed/MEDLINE, Scopus, and Web of Science Core Collection, with Google Scholar used as a supplementary source, together with manual screening of the reference lists of relevant original studies, clinical trials, reviews, consensus documents, and clinical guidelines. The principal literature search covered publications from January 2010 to March 2026, while selected seminal primary studies published before 2010 were included when necessary to document the original identification of pathogenic FGFR3 variants and foundational mechanisms of FGFR3-mediated growth plate regulation. Particular emphasis was placed on FGFR3 variants, receptor activation mechanisms, growth plate dysfunction, intracellular signaling pathways, vosoritide, C-type natriuretic peptide-based therapies, FGFR3 inhibitors, ligand-receptor blockade, drug repurposing, Wnt/β-catenin modulation, and gene-based therapeutic approaches.<h4>Results</h4>Achondroplasia is characterized by marked molecular homogeneity, with the recurrent p.Gly380Arg substitution accounting for most cases. Mutant FGFR3 displays sustained activity through partial ligand independence, enhanced receptor dimerization and kinase activation, increased receptor stability, and reduced degradation. Excessive signaling through MAPK/ERK, STAT, PI3K/AKT, IHH/PTHrP, and related pathways impairs chondrocyte proliferation and hypertrophic differentiation, alters extracellular matrix turnover, disrupts primary cilium function, and reduces longitudinal bone growth. Vosoritide provides clinical proof that pharmacological modulation of FGFR3-related signaling can improve growth velocity. Additional therapeutic strategies under clinical or preclinical investigation include long-acting CNP analogues, selective FGFR inhibitors, decoy receptors, RNA aptamers, repurposed drugs, Wnt/DKK1 pathway modulation, and gene- or enhancer-targeted interventions.<h4>Conclusions</h4>Achondroplasia is increasingly understood as a disorder of dysregulated growth plate signaling rather than solely a condition of reduced stature. Although vosoritide has established the feasibility of disease-modifying treatment, substantial uncertainty remains regarding final adult height, skeletal proportionality, cranio-spinal development, orthopedic outcomes, and long-term safety. Future progress will depend on mechanistically informed therapeutic combinations, improved biomarkers, advanced cellular and animal models, and long-term clinical and real-world evidence.
Background
This review addresses the genetic and molecular mechanisms underlying achondroplasia, a common skeletal dysplasia characterized by disproportionate short stature. Prior knowledge indicates that achondroplasia is linked to mutations in the FGFR3 gene, leading to disrupted growth plate function. Understanding these mechanisms is crucial for developing targeted therapies, moving beyond supportive management to disease-modifying treatments.
Methods
The authors conducted a narrative literature review using databases such as PubMed/MEDLINE, Scopus, and Web of Science, with a focus on publications from January 2010 to March 2026. They included seminal studies published before 2010 to document foundational mechanisms of FGFR3-mediated growth plate regulation. The review emphasizes various therapeutic strategies, including vosoritide and other emerging treatments.
Results
The review highlights that excessive signaling through pathways like MAPK/ERK and PI3K/AKT impairs chondrocyte function and reduces bone growth. Vosoritide is mentioned as a pharmacological agent that has shown proof of concept in improving growth velocity. However, specific numeric findings related to growth velocity improvement are not reported in the abstract.
Interpretation
The findings suggest that while vosoritide has established the feasibility of disease-modifying treatment for achondroplasia, the clinical significance of its effects on growth velocity and other long-term outcomes remains uncertain. The review indicates that further research is needed to clarify the implications of these treatments, especially regarding adult height and orthopedic outcomes. Limitations include the narrative nature of the review, which may not capture all relevant data from clinical trials.
Key findings
- Achondroplasia is primarily caused by gain-of-function variants in the FGFR3 gene.
- The recurrent p.Gly380Arg substitution accounts for most cases of achondroplasia.
- Vosoritide provides clinical proof that pharmacological modulation of FGFR3-related signaling can improve growth velocity.
- Substantial uncertainty remains regarding final adult height, skeletal proportionality, cranio-spinal development, orthopedic outcomes, and long-term safety.
Limitations
- This is a narrative review, lacking quantitative data.
- No specific numeric findings on growth velocity improvement reported.
- Substantial uncertainty regarding long-term outcomes and safety.